The analysis reveals a troubling divide in early-stage cancer detection rates between high-income countries (HICs) and low- and middle-income countries (LMICs). For breast and cervical cancers, roughly 40% of women in wealthier nations were diagnosed at an early stage, while this figure falls below 20% in poorer regions. Notably, ovarian cancer emerges as the cancer least likely to be caught early, with fewer than one in five cases detected at an early phase globally. This disparity underscores not only diagnostic challenges but also the broader barriers to timely healthcare access in less resourced settings.

One key driver of survival outcomes is the stage at which cancer is detected. Metastatic breast cancers, where malignant cells have spread beyond the primary site, account for under 10% of cases in most high-income contexts, but can reach upwards of 44% in some LMICs. Advanced cervical cancer rates show similarly concerning variations, though generally remain beneath 15% worldwide. Ovarian cancers, often dubbed the “silent killer” due to nonspecific symptoms such as abdominal pain and swelling, frequently evade early detection, with diagnoses skewed heavily towards advanced stages across all countries.

Treatment modalities and their adherence to clinical guidelines also vary widely. Surgery, a cornerstone of cancer management, is offered to 78% of women with early-stage disease in HICs, compared to just 56% in LMICs. However, the choice and appropriateness of surgical interventions reveal a complex global mosaic. For example, breast-conserving surgery followed by radiotherapy—the guideline-recommended approach for early-stage breast cancer—is practiced in 67-78% of cases in most European countries, but see lower rates in North America. In contrast, mastectomy remains common not only in LMICs but also in countries like the United States and Canada, reflecting multifaceted factors including patient preference, healthcare infrastructure, and insurance coverage.

The domination of mastectomy in LMICs is primarily attributed to limited availability of radiotherapy and scarcity of surgeons specializing in breast conservation techniques. Beyond technical constraints, socioeconomic determinants such as health literacy, distance from treatment centers, and cultural perceptions critically influence treatment decisions. In Thailand, for instance, older women often choose mastectomy driven by beliefs about its superior curative potential, whereas in parts of the United States, insurance policies may restrict access to radiotherapy, disproportionately affecting economically disadvantaged patients.

This study was conducted under the VENUSCANCER project, nested within the larger CONCORD programme which monitors global cancer survival. It harnesses population-based cancer registries—data repositories essential to understanding epidemiologic and treatment patterns at scale. The authors emphasize the irreplaceable role of these registries in benchmarking clinical care and guiding public health policies, urging sustainable governmental investment in maintaining and expanding such data infrastructure, especially in LMICs where data completeness often lags.

Another significant insight from the study is the relationship between patient age and treatment adherence to guidelines. Both in high- and low-income settings, older women were less frequently offered treatments aligned with established protocols compared to their younger counterparts. This discrepancy highlights an urgent need for individualized care approaches that transcend ageist biases and consider physiological as well as social contexts to optimize outcomes.

Importantly, non-surgical interventions such as chemotherapy and hormone therapies demonstrated higher adherence to clinical guidelines than surgery in many countries. This suggests that systemic treatments may be more uniformly accessible or standardized globally, although this doesn’t diminish the critical need to expand surgical capacity and expertise. Radiotherapy facilities, in particular, are acutely lacking in many LMICs, further complicating efforts to offer comprehensive, guideline-consistent treatment.

Lead researcher Professor Claudia Allemani from the London School of Hygiene & Tropical Medicine underscores that while early-stage detection combined with prompt access to optimal treatment is increasingly attainable, especially in wealthier nations, the persisting low rates of early diagnosis in LMICs severely limit survival improvements. She advocates for intensified global policy actions, including expanded cancer screening programs, investment in healthcare infrastructure, and tailored clinical guidelines that reflect local realities and resource constraints.

Moreover, Dr. Veronica Di Carlo highlights the imperative of adapting international recommendations to diverse healthcare environments. Simplification and translation of clinical guidelines into local languages, coupled with educational initiatives for healthcare providers and patients alike, could significantly enhance guideline implementation worldwide. Ensuring women have informed agency in treatment decisions not only improves adherence but also respects individual values and cultural contexts.

While the study represents a monumental step forward, authors acknowledge limitations such as incomplete data from certain countries, which may affect generalizability of findings. Nonetheless, the wealth of evidence produced sets a new benchmark for understanding global cancer care pathways and illuminates critical avenues for intervention.

The implications of these revelations are profound. With cancer representing a leading cause of death among women globally, bridging the gaps in early detection and treatment consistency is an urgent public health priority. Enhanced funding for population-based cancer registries, expanded radiotherapy infrastructure, increased training for specialized surgeons, and reforms in health insurance coverage collectively form the pillars on which global oncology equity must be built.

This monumental study, published in The Lancet, is poised to inform and energize initiatives such as the World Health Organization’s Global Breast Cancer Initiative and Cervical Cancer Elimination Initiative. Its findings advocate for a concerted, multifaceted approach to cancer control that transcends economic divides, ensuring that all women, regardless of geography or income, receive high-quality, timely, and guideline-consistent cancer care.

Subject of Research: Global disparities in diagnosis, treatment, and guideline adherence for breast, cervical, and ovarian cancers in women.

Article Title: Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275,792 women from 103 population-based cancer registries in 39 countries and territories.

News Publication Date: 22-Oct-2025

Web References:

• VENUSCANCER Project: https://cordis.europa.eu/project/id/772345
• CONCORD Programme: https://csg.lshtm.ac.uk/research/themes/concord-programme/
• DOI Link: http://dx.doi.org/10.1016/S0140-6736(25)01383-2

References: Study published in The Lancet, 2025.

Keywords: Health and medicine, Cancer, Epidemiology, Cervical cancer, Breast cancer, Ovarian cancer

Ovarian cancer, a malignancy known for its silent progression and late-stage diagnosis globally, presents unique challenges in conflict zones where routine health screenings and timely interventions are scarce. Syria’s prolonged war has disrupted hospital infrastructure, impeded patient access, and caused data scarcity, making this study a critical source of novel insights. By examining patient records from three major university hospitals — Tishreen, Al-Bairouni, and Ibn Rushd — researchers compiled comprehensive data on patient demographics, tumor subtypes, symptomatology, and relevant biomarkers such as CA-125 levels.

The study encompassed 531 newly diagnosed ovarian cancer patients, with ages ranging broadly from young adults of 18 years to the elderly reaching 91. The mean patient age was 53.1 years, paralleling global trends that identify middle-aged women as the most affected demographic. Despite the presumed high burden of ovarian cancer in the general population, in this sample, ovarian cancer accounted for only 1.2% of all cancer cases diagnosed over the study period, signaling a likely underreporting or underdiagnosis phenomenon influenced by war-driven healthcare disruptions.

Histopathological analysis revealed that serous carcinoma dominated the ovarian cancer subtypes, representing more than half (55.4%) of cases. This aligns with international data where high-grade serous carcinoma is the predominant form of ovarian malignancy worldwide. Mucinous and endometrioid carcinomas were the next most common, at 13.8% and 9.7% respectively, showcasing tumor heterogeneity consistent with established oncological classifications.

The study’s laboratory findings underline the importance of CA-125, a well-known serum biomarker often elevated in epithelial ovarian cancers. Elevated CA-125 levels were significantly associated with serous carcinoma, exhibiting an adjusted odds ratio of 2.30. Conversely, lower CA-125 levels correlated with endometrioid cancer, highlighting that although CA-125 is useful diagnostically, its interpretation must consider tumor histology. This biomarker’s role in diagnosis, prognosis, and monitoring remains pivotal, especially in settings with limited imaging resources.

Clinically, abdominal bloating emerged as the most commonly reported presenting symptom, affecting 36.5% of the patient cohort. This symptom’s prominence echoes extensive research identifying nonspecific abdominal or pelvic discomfort as a hallmark of ovarian malignancy’s stealthy progression. Unfortunately, nonspecific symptoms such as bloating often masquerade as benign conditions, delaying diagnosis and worsening outcomes, particularly in regions lacking robust screening protocols.

The relatively low proportion of ovarian cancer cases relative to all cancers in Syria is emblematic of broader systemic challenges. The study suggests that underdiagnosis, late presentation, and barriers to accessing specialized care are exacerbated by the protracted conflict. Women, in particular, may face compounded obstacles due to cultural norms, displacement, and resource scarcity, ultimately skewing epidemiological data and obscuring the true disease burden.

Given these complexities, the authors emphasize the necessity for expanded epidemiological efforts and improved diagnostic infrastructure to capture a more accurate picture of ovarian cancer incidence in Syria. Strengthening cancer registries, promoting awareness, and integrating ovarian cancer screening in primary healthcare—even amid conflict—are critical steps toward mitigating disease impact.

Moreover, this study’s retrospective design and reliance on tertiary hospital data may not encompass rural or internally displaced populations, highlighting the importance of future prospective research initiatives. Such investigations are crucial for unpacking the intricate interplay between war-related factors and cancer epidemiology, potentially guiding tailored interventions.

In addition to epidemiological data, this research underscores the broader implications of healthcare disruption on oncological outcomes. Delayed diagnoses frequently result in advanced-stage presentations with limited treatment options, underscoring a grim consequence of the ongoing conflict on cancer survival rates. International support and targeted healthcare policies could ameliorate these gaps, improving diagnostic and therapeutic accessibility.

The findings also resonate beyond Syrian borders, serving as a case study for how conflict zones affect cancer control globally. This comparative perspective highlights a pressing need for international oncology communities to address cancer care in humanitarian crises, advocating for resilient health systems that accommodate cancer patients even under duress.

Ultimately, this comprehensive study offers a foundational understanding of ovarian cancer’s epidemiology during one of Syria’s most challenging periods. It provides vital data that can inform healthcare planning, resource allocation, and advocacy, driving the agenda for enhanced cancer control strategies amid continuing instability.

The elevated prevalence of serous carcinoma, the nuanced role of CA-125, and the predominance of abdominal bloating as a presenting symptom contribute to refining clinical suspicion in resource-limited settings. These insights could enable clinicians to prioritize differential diagnoses and expedite timely referrals, potentially improving patient outcomes.

While this work addresses critical knowledge gaps, it also opens avenues for multidisciplinary collaborations integrating oncology, public health, and humanitarian medicine. Future research might explore genetic factors, treatment outcomes, and psychosocial barriers to care, deepening understanding in a context marked by adversity yet underscored by scientific resilience.

In summary, the study portrays a striking depiction of ovarian cancer within war-affected Syria, melding clinical findings with epidemiological nuance. It calls for renewed global attention to neglected diseases in fragile contexts and emphasizes the indispensable role of comprehensive cancer surveillance in informing health policy during times of crisis.

The study’s authors poignantly remind us that behind each statistic lies a human story compounded by war, displacement, and limited healthcare access—underscoring that combating ovarian cancer in Syria demands concerted effort, innovative strategies, and unwavering commitment.

Subject of Research: Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years (2017–2021)

Article Title: Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years: a national multicenter retrospective study (2017–2021)

Article References:
Apelian, S., Hamdan, A., Mohammad, R. et al. Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years: a national multicenter retrospective study (2017–2021). BMC Cancer 25, 1359 (2025). https://doi.org/10.1186/s12885-025-14784-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14784-8

Although the omentum is defined as a membrane structure covered with fatty tissue that covers the intra-abdominal organs, it is a functionally active tissue that contains many elements related to the immune system. While the lymphoid structures called milky spots make it possible to think that this tissue plays an active role in immune defense, it is observed that it plays the opposite role in tumors such as ovarian cancer, facilitating the spread of cancer. This contradiction brings with it the question of whether the omentum is a friend or an enemy.

A new scientific publication that examines the opposing roles of the omentum in detail addresses the immunological and tumor-supporting functions of this structure and questions whether it is a potential target in the fight against ovarian cancer. According to the publication in question, although the omentum may seem like an immune area that will prevent tumor spread at first glance, in practice, cancer cells use this structure as a springboard and contribute to the spread of peritoneal carcinomatosis.

The milky spot structures in the omentum have functions such as antigen presentation, cytokine release and regulation of the immune response with their complex structures consisting of T and B lymphocytes, natural killer cells, macrophages and dendritic cells. However, in ovarian cancer, these immune structures cannot provide an effective defense against tumor cells, on the contrary, they create a tolerogenic environment that will allow these cells to settle.

In particular, the dominance of CD163+ Tim4+ macrophages in the omentum forms the basis of the immunosuppressive microenvironment. This macrophage subgroup prevents T-cell activation, facilitating the growth of tumor cells without being noticed. However, the dense vascular network and environmental signals of the omentum further facilitate the invasion and spread of tumor cells.

Another reason why the omentum is attractive to tumors is from a metabolic perspective. This region, filled with fatty tissue, provides an energy source for ovarian tumor cells. Tumor cells gain the ability to proliferate rapidly by using lipids taken from adipocytes in the omentum. This situation makes the omentum suitable for cancer not only in terms of microsystemic but also metabolic adaptation.

Another important feature of the omentum is that it is the primary settlement area in both transperitoneal spread and hematological (blood-borne) metastasis. Studies show that the omentum also attracts tumor cells coming from the bloodstream with specialized signals such as neuregulin-1 (NRG1). Ovarian tumor cells carrying the HER3 receptor perceive these signals and attach to the omentum and proliferate there.

Despite all this, the possibility that the omentum can also be used as a potential defense weapon has been a topic of discussion recently. It is suggested that immunotherapy strategies directed intraperitoneally (into the abdomen) in particular can create an anti-tumor response by activating milky spot structures. Experiments in mouse models have shown that the omentum has the capacity to create such specific responses.

In these experiments, it was observed that dendritic cells were activated in the omentum and both CD4+ and CD8+ T cells were specifically activated as a result of intraperitoneal injection of tumor cells killed with radiation. This shows that the omentum is actually a potential source of immune response and can be reprogrammed to fight tumors.

The use of the omentum as a defense mechanism includes not only T cells but also natural killer (NK) cells. It has been determined that NK cells are effective against both specific and non-specific tumors when activated in the omentum. This makes it possible to design new generation immunotherapy approaches such as CAR-T as omentum-targeted.

Of course, this double-sided structure of the omentum also affects surgical approaches. Although omentectomy (removal of the omentum), which has become almost standard in advanced ovarian cancer cases today, seems logical due to the tumor-supporting role of this tissue, it can actually mean the elimination of a potential immune defense center. Therefore, advanced biomarker analyses should be used to determine in which patient the omentum should be preserved.

The omentum can be both a metastatic nest and an immunological fortress. The direction in which it can be turned will be the focus of future immunotherapy strategies. Like a sword, it can save lives or cause death, depending on how it is used.

Subject of Research: Immunological and metastatic functions of the omentum in ovarian cancer

Article Title: Omentum: Friend or foe in ovarian cancer immunotherapy?

News Publication Date: April 2, 2025

Web References: https://doi.org/10.1016/bs.ircmb.2022.04.017

References: Bella A., Arrizabalaga L., Di Trani C.A., et al. (2022). Omentum: Friend or foe in ovarian cancer immunotherapy? International Review of Cell and Molecular Biology, 371, 117–131.

Keywords: Ovarian cancer, omentum, peritoneal carcinomatosis, milky spots, CD163+ Tim4+ macrophage, immunotherapy, metastasis, HER3, NRG1, CAR-T, TGF-β, VEGF, Treg, CD8+ T cell, NK cell, immunosuppression